Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway
about
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.A New Double Stranded RNA Suppresses Bladder Cancer Development by Upregulating p21 (Waf1/CIP1) Expression.Negative Regulation of p21Waf1/Cip1 by Human INO80 Chromatin Remodeling Complex Is Implicated in Cell Cycle Phase G2/M Arrest and Abnormal Chromosome Stability.Prognostic Significance of Tag SNP rs1045411 in HMGB1 of the Aggressive Gastric Cancer in a Chinese Population.HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma cells by activating NF-κB.PTTG1 regulated by miR-146a-3p promotes bladder cancer migration, invasion, metastasis and growth.Loss of BRG1 induces CRC cell senescence by regulating p53/p21 pathway.Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 (CIP1/WAF1) expression.Oncogenic STRAP functions as a novel negative regulator of E-cadherin and p21(Cip1) by modulating the transcription factor Sp1.Crataegus azarolus Leaves Induce Antiproliferative Activity, Cell Cycle Arrest, and Apoptosis in Human HT-29 and HCT-116 Colorectal Cancer Cells.Signaling pathways activation profiles make better markers of cancer than expression of individual genes.The dual role and therapeutic potential of high-mobility group box 1 in cancer.Identification of TDP-43 as an oncogene in melanoma and its function during melanoma pathogenesis.Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.
P2860
Q26746478-F93A513A-C9DD-4782-B7D3-5416D9EA3EB6Q28548486-9FAE8562-EE35-482A-9F4C-965F8BF0C89CQ35402181-B0D71394-2426-4811-8536-8BD207276FADQ35764584-20568BE2-C670-4994-B7A4-F84F55DF64C4Q35999764-F255563C-FDD2-47FE-A867-9921D0B4B679Q36834531-BE306D52-4DCD-477C-9952-2ED9D8E983DBQ37697068-18630E53-88EF-4739-8B59-075842DFD4CBQ37702335-B4DFD722-B27B-44E9-B534-A3C75C622C21Q37745174-68689510-DD42-4AD5-A013-52423E388C64Q38813869-BDEFBBC4-E1F6-43F0-B6F6-E82588333B89Q38931408-F296B2B0-A6B1-467C-84CF-54DE61089B25Q40399054-86DFAE4F-B357-4331-B1FE-C8C2534FE98FQ41874902-255482C4-254A-4F6D-A4BE-4AEFAD455776Q42362799-9071A517-745C-41BB-9125-30A05D3AEA22Q42560911-C4F178B5-7E36-4255-81E4-8BCA758F54EBQ52145169-C92F130A-D151-4D7A-AA1B-35E165DFF03A
P2860
Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@ast
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@en
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@nl
type
label
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@ast
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@en
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@nl
prefLabel
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@ast
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@en
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@nl
P2093
P2860
P356
P1433
P1476
Overexpression of HMGB1 in mel ...... pendent, Sp1-dependent pathway
@en
P2093
Aiyuan Guo
Chong Zhang
Honghao Zhou
Jieqiong Tan
Minghao Jiang
Qingling Li
P2860
P304
P356
10.18632/ONCOTARGET.2201
P407
P577
2014-08-01T00:00:00Z